139183-87-2Relevant articles and documents
THERAPEUTIC INHIBITORY COMPOUNDS
-
, (2015/07/16)
The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.
ANTIVIRAL COMPOUNDS AND USE THEREOF
-
Page/Page column 30, (2009/12/02)
The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.
Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design
Choong, Ingrid C.,Lew, Willard,Lee, Dennis,Pham, Phuongly,Burdett, Matthew T.,Lam, Joni W.,Wiesmann, Christian,Luong, Tinh N.,Fahr, Bruce,DeLano, Warren L.,McDowell, Robert S.,Allen, Darin A.,Erlanson, Daniel A.,Gordon, Eric M.,O'Brien, Tom
, p. 5005 - 5022 (2007/10/03)
The design, synthesis, and in vitro activities of a series of potent and selective small-molecule inhibitors of caspase-3 are described. From extended tethering, a salicylic acid fragment was identified as having binding affinity for the S4 pocket of caspase-3. X-ray crystallography and molecular modeling of the initial tethering hit resulted in the synthesis of 4, which reversibly inhibited caspase-3 with a Ki = 40 nM. Further optimization led to the identification of a series of potent and selective inhibitors with Ki values in the 20-50 nM range. One of the most potent compounds in this series, 66b, inhibited caspase-3 with a Ki = 20 nM and selectivity of 8-500-fold for caspase-3 vs a panel of seven caspases (1, 2, and 4-8). A high-resolution X-ray cocrystal structure of 4 and 66b supports the predicted binding modes of our compounds with caspase-3.
